Drugs / LX102
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06198413 | Feb 2023 → Dec 2024 overdue | wet macular degeneration | Innostellar Biotherapeutics Co.,Ltd | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06196840 | Jan 2024 → Jun 2025 overdue | wet macular degeneration | Innostellar Biotherapeutics Co.,Ltd | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07317934 | Jan 2026 → Mar 2028 expected | wet macular degeneration | Innostellar Biotherapeutics Co.,Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LX102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06198413 ↗ |
| Action | Inhibit | “LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap” NCT06196840 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap” NCT06196840 ↗ |